Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells

Sun,Yuan-Wan; Niu,Ting-Kuang; Yang,Jin-Ming; Kwon,Chul-Hoon; Chen,Kuen-Yuan; Chen,Kun-Ming

doi:10.3892/etm_00000081

Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells

Authors:
- Yuan-Wan Sun
- Ting-Kuang Niu
- Jin-Ming Yang
- Chul-Hoon Kwon
- Kuen-Yuan Chen
- Kun-Ming Chen
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA
Published online on: May 1, 2010 https://doi.org/10.3892/etm_00000081
Pages: 513-518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The 9-aminoacridine derivative, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) was selected as a potential anticancer agent among a series of sulfur-containing 9-aminoacridine analogues. CK0402 is a topoisomerase II inhibitor and has been shown to exert impressive anticancer activities in both in vitro and in vivo assays. In the present study, we tested the effects of CK0402 in a panel of established human breast cancer cells with varying ER and HER2/neu status. The ER(−) and HER2-overexpressing SKBR-3 cells were the most sensitive cells tested in growth inhibition to CK0402 treatment, and the growth inhibition was in a time- and concentration-dependent manner. In addition, CK0402 also induced stronger G2/M arrest, apoptosis and autophagy in SKBR-3 cells than in ER(+) and HER2(−) MCF-7 cells. To the best of our knowledge, CK0402 is the first 9-aminoacridine analogue to induce autophagy. These findings suggest that CK0402 may be effective against the more aggressive and malignant ER(−) and HER2-overexpressing breast cancer. Towards this end, we further demonstrated that the combination of CK0402 and Herceptin exhibited synergistic/additive cytotoxic effects in SKBR-3 cells using the median-effect/combination-index isobologram methodology (CI value). Our results indicate that the combination of CK0402 and Herceptin may be a potential therapeutic option against the more aggressive ER(−) and HER2-overexpressing breast cancer.

View Figures

View References

1.	Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
2.	Gianni L and Valagussa P: Anthracyclines and early breast cancer: the end of an era? J Clin Oncol. 27:1155–1157. 2009. View Article : Google Scholar : PubMed/NCBI
3.	O’Shaughnessy J: Liposomal anthracyclines for breast cancer: overview. Oncologist. 8(Suppl 2): 1–2. 2003.
4.	Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 58:351–375. 1989. View Article : Google Scholar : PubMed/NCBI
5.	Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Chen KM, Sun YW, Tang YW, Sun ZY and Kwon CH: Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines. Mol Pharm. 2:118–128. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Park SK, Kang H and Kwon CH: Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine. Anticancer Drugs. 19:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Baguley BC, Holdaway KM and Fray LM: Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst. 82:398–402. 1990. View Article : Google Scholar : PubMed/NCBI
10.	Jarvinen TA and Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes – molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets. 6:579–602. 2006.
11.	Jorgensen JT, Nielsen KV and Ejlertsen B: Pharmacodiagnostics and targeted therapies – a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 12:397–405. 2007.
12.	Smith I and Chua S: Medical treatment of early breast cancer. IV: neoadjuvant treatment. BMJ. 332:223–224. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 232:123–138. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
15.	Smith K, Houlbrook S, Greenall M, Carmichael J and Harris AL: Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 8:933–938. 1993.PubMed/NCBI
16.	Amaravadi RK and Thompson CB: The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 13:7271–7279. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Klionsky DJ, Abeliovich H, Agostinis P, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 4:151–175. 2008. View Article : Google Scholar
18.	Baldwin EL and Osheroff N: Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 5:363–372. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS and Marks JR: Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 18:2919–2932. 1998.PubMed/NCBI
20.	Houlbrook S, Addison CM, Davies SL, et al: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer. 72:1454–1461. 1995. View Article : Google Scholar : PubMed/NCBI
21.	Mano MS, Rosa DD, De Azambuja E, Ismael GF and Durbecq V: The 17q12–q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev. 33:64–77. 2007.
22.	Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O’Malley F and Dhesy-Thind B: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 26:736–744. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Haldane A, Holdaway KM, Finlay GJ and Baguley BC: Cytokinetic differences in the action of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemother Pharmacol. 32:463–470. 1993.
24.	Morse DL, Gray H, Payne CM and Gillies RJ: Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 4:1495–1504. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Bursch W, Ellinger A, Gerner C, Frohwein U and Schulte-Hermann R: Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann NY Acad Sci. 926:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
26.	Hoyer-Hansen M and Jaattela M: Autophagy: an emerging target for cancer therapy. Autophagy. 4:574–580. 2008. View Article : Google Scholar
27.	Yu L, Wan F, Dutta S, et al: Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA. 103:4952–4957. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Ma WW and Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 59:111–137. 2009. View Article : Google Scholar : PubMed/NCBI